A preclinical study published in Biological Psychiatry has found that repeated low doses of psilocybin and MDMA reshape ...

Participants in an IFS PTSD-SUD (substance use disorder) intervention experienced reduced PTSD symptoms and cravings, making it a promising public health treatment option.

A novel, non-hallucinogenic, experimental drug shows statistically significant, rapid, and durable improvement in PTSD symptom severity in a phase 2 trial.

New research reveals that psilocybin and MDMA promote long-term PTSD recovery by physically remodeling myelin insulation in ...

Research provides evidence that veterans can effectively self-administer microcurrent point stimulation (MPS) at home ...

Quitting cannabis may yield greater improvements in PTSD symptoms than continued use in adults with both PTSD and cannabis ...

Post-traumatic stress disorder (PTSD) is not only characterized by strongly encoded traumatic memories, but also by disrupted coordination across brain networks. New research shows that treatment with ...

A psychoactive drug derived from an African plant could transform treatment for addiction and PTSD. Here’s why Tennessee ...

DoD-Funded Study Accelerates Novel PTSD Mechanism into Trials; Proven Alcohol Safety Profile De-Risks Program for ...

FDA Accepts Investigational New Drug (IND) Application for COMP360 for the treatment of post-traumatic stress disorder (PTSD), enabling initiation of late-stage trial Compass continues to advance ...

A sympathetic nerve block that has shown promise for treatment of post-traumatic stress disorder (PTSD) performed no better than sham treatment in a randomized controlled trial, new research shows.